Initially, the use of antibody-drug conjugates, such as trastuzumab-deruxtecan (T-DXd), has been recommended for HER2-positive patients with metastatic disease, corresponding to those with IHC scores of 3+, or 2+ with gene amplification confirmed by ISH. Here, ERBB2 is linked to metastatic neoplasm.